These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 18384706)

  • 1. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics and the pharmacological management of depression.
    Krauter RR; Cook SS
    Nurse Pract; 2011 Oct; 36(10):14-21; quiz 21-2. PubMed ID: 21937968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.
    Mirzakhani H; van Dormolen J; van der Weide K; Guchelaar HJ; van Noorden MS; Swen J
    Pharmacogenet Genomics; 2015 Oct; 25(10):515-7. PubMed ID: 26230381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
    Lee SY; Ki CS; Hong KS; Kim JW
    J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.
    Zourková A; Cesková E; Hadasová E; Ravcuková B
    J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    D'Empaire I; Guico-Pabia CJ; Preskorn SH
    J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
    Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
    Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
    Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
    J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
    Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
    Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
    Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
    Haffen E; Vandel P; Paintaud G; Broly F; Vandel S; Bonin B; Bizouard P; Sechter D; Bechtel PR
    Eur J Clin Pharmacol; 2000; 55(11-12):877-9. PubMed ID: 10805068
    [No Abstract]   [Full Text] [Related]  

  • 19. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.